F-1/A: Polyrizon Ltd. Eyes Nasdaq Listing with Proposed IPO of Units and Pre-Funded Units

Polyrizon Ltd., a biotech company specializing in nasal spray hydrogels, is planning an initial public offering to fund the development of its medical device product candidates.

Summary

• Polyrizon Ltd., a development stage biotech company, is planning an initial public offering (IPO) to raise funds for its operations.
• The company specializes in developing innovative medical device hydrogels delivered as nasal sprays.
• These nasal sprays are designed to create a barrier against viruses and allergens in the nasal cavity.
• The IPO includes offering 807,692 units, each consisting of one ordinary share and three warrants, with an expected price between $4.38 and $6.02 per unit.
• The company is also offering pre-funded units to purchasers who would otherwise exceed ownership limits.
• The company intends to list its ordinary shares on The Nasdaq Capital Market under the symbol PLRZ.
• The company plans to use the net proceeds from the offering for preclinical and clinical development of its PL-14, PL-15 and PL-16 product candidates, in vitro feasibility studies of corticosteroid, benzodiazepine, naloxone for its T&T platform technology product candidates, repay certain convertible loans, and for working capital and general corporate purposes and possible future acquisitions.
• Certain existing shareholders have indicated an interest in purchasing up to $1 million of Units in this offering.

Sentiment

Score: 5

Explanation: The document presents a balanced view, highlighting both the potential of Polyrizon's technology and the risks associated with its development and commercialization. The company's financial situation and dependence on future funding are also key considerations.

Positives

• The company's nasal hydrogels are designed to be non-invasive and fast-acting.
• The mucoadhesive polymers used in the hydrogels are derived from seaweed polysaccharides, which are renewable, biodegradable, biocompatible, and environment friendly.
• The company's leadership team has extensive experience in the life sciences industry.
• The company has secured an exclusive patent license agreement with SciSparc for its SCI-160 platform.
• The company has a collaboration agreement with NurExone Biologic Inc. to develop formulations for intranasal delivery of ExoTherapy.

Negatives

• The company has incurred significant losses since its inception and anticipates continuing to incur losses for the foreseeable future.
• The company has never generated any revenue from product candidate sales and may never be profitable.
• The company expects that it will need to raise substantial additional funding, which may not be available on acceptable terms, or at all.
• The company is heavily dependent on the success of its C&C product candidates.
• The company's C&C and T&T technologies are novel technologies, which makes it difficult to accurately and reliably predict the time and cost of development and regulatory approval.

Risks

• The company may not receive, or may be delayed in receiving, the necessary clearances or approvals for its product candidates.
• The company does not plan to conduct a pre-submission meeting with the FDA for its PL-15 and PL-16 products until after the IPO.
• The company faces intense competition in an environment of rapid technological change.
• The company relies on third parties to manufacture the raw materials that it uses to create its product candidates.
• The company's headquarters and other significant operations are located in Israel, and, therefore, its results may be adversely affected by political, economic and military instability in Israel.
• The market price of the company's securities may be highly volatile, and investors may not be able to resell their Ordinary Shares at or above the initial public offering price.

Future Outlook

The company expects its expenses and operating losses to increase for the foreseeable future as it continues clinical development of its C&C product candidates and develops other product candidates using its T&T platform technology.

Industry Context

The nasal spray market is expected to grow significantly, driven by rising infections, allergic conditions, and the convenience of nasal drug delivery systems.

Comparison to Industry Standards

• The FDA submission and clearance process for Polyrizon's predicate devices for its PL-14 product candidate, Alzair, Nasalese and Bentrio, took 86 and 140 days, respectively.
• The global cold and cough remedies market is valued at $42.65 billion in 2024 and is expected to grow at a CAGR of 6.18% from 2024 to 2029.
• The global therapeutic market for allergic rhinitis is projected to reach $16 billion by 2032, growing at a CAGR of 2.5% from 2023 to 2032.
• The global allergen blocker market will reach $214.5 million in 2030, growing at a CAGR of 3.64% during 2023-2030.
• The global market for intranasal drug delivery is projected to reach $136.46 billion by 2032, growing at a CAGR of 7.18%.
• The INCS products market is estimated to reach $11.2 billion by 2033.
• The benzodiazepines drug market is expected to reach $4.2 billion by 2032, which reflects a CAGR of 3.7% during 2024-2032.
• The market for Benzodiazepines for seizure clusters is estimated to be around $700 million.
• The global naloxone market is expected to grow to $2.47 billion in 2032, at a CAGR of 11% between 2023 and 2032.
• The naloxone intranasal spray market is projected to attain a value of $1.4 billion by 2030.
• The global pain management drugs market size was estimated at $78.14 billion in 2022 and is projected to hit around $115 billion by 2032, growing at a CAGR of 3.94% during the forecast period 2023 to 2032.

Related Party Transactions

• XYLO Technologies Ltd. Share Purchase Agreements
• August 2021 Share Purchase Agreement
• June 2023, December 2023 and May 2024 Share Purchase Agreements
• Convertible Loan with XYLO
• Convertible Loan with Reuven Srugo Construction Company Ltd.

Stakeholder Impact

• Shareholders: Dilution of ownership due to the issuance of new shares.
• Employees: Potential for job creation and career advancement as the company grows.
• Customers: Access to innovative medical device hydrogels for nasal delivery.
• Suppliers: Increased demand for raw materials and manufacturing services.
• Creditors: Repayment of convertible loans.

Next Steps

• Complete preclinical development for PL-14, PL-15 and PL-16 product candidates.
• Complete clinical development for PL-14 product candidate.
• Complete in vitro feasibility studies of corticosteroid, benzodiazepine, naloxone for T&T platform technology product candidates.
• Repay the April 2024 CLA and August 2024 CLA.
• Submit a 510(k) application for FDA clearance for PL-14 product candidate.
• Submit De Novo Classification requests for PL-15 and PL-16 product candidates.
• Start an initial testing to explore the potential of SCI-160 platform when combined with the T&T technology.

Key Dates

Keywords

Polyrizon, IPO, hydrogels, nasal sprays, medical devices, pharmaceutical, clinical trials, FDA, warrants, pre-funded units